Kymera Therapeutics Inc (KYMR) reports robust financial health and strategic advancements, setting the stage for significant ...

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and ChinaTopline ...

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

Boston, USA-based biotech Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from ...

Novavax (NASDAQ:NVAX) shares traded marginally higher on Thursday in the premarket after the Gaithersburg, Maryland-based ...

Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is ...

Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025KT-621 Phase 1b trial in atopic dermatitis ...

Novavax's net loss was $81 million for the quarter ended December 31, compared with a net loss of $178.3 million a year ago.